Disease or Syndrome: Leukoencephalopathy, Progressive Multifocal

Medical news and research articles

First biosimilar approved to treat multiple sclerosis

The U.S. Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection, for the treatment of relapsing forms of multiple sclerosis, the agency announced Thursday.

page 1 from 1